Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Burger, Maximilian ; Oosterlinck, Willem ; Konety, Badrinath ; Chang, Sam ; Gudjonsson, Sigurdur LU ; Pruthi, Raj ; Soloway, Mark ; Solsona, Eduardo ; Sved, Paul and Babjuk, Marko , et al. (2013) In European Urology 63(1). p.36-44
Abstract
Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective... (More)
Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Bacillus Calmette-Guerin (BCG), Bladder cancer, Cystoscopy, Diagnosis, Guidelines, Intravesical chemotherapy, Prognosis, Transurethral, resection (TUR)
in
European Urology
volume
63
issue
1
pages
36 - 44
publisher
Elsevier
external identifiers
  • wos:000312004100010
  • scopus:84870477356
  • pmid:22981672
ISSN
1873-7560
DOI
10.1016/j.eururo.2012.08.061
language
English
LU publication?
yes
id
71b80dcd-cc85-495d-ad33-2502013e43ba (old id 3400916)
date added to LUP
2016-04-01 13:32:56
date last changed
2022-02-04 08:03:20
@article{71b80dcd-cc85-495d-ad33-2502013e43ba,
  abstract     = {{Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.}},
  author       = {{Burger, Maximilian and Oosterlinck, Willem and Konety, Badrinath and Chang, Sam and Gudjonsson, Sigurdur and Pruthi, Raj and Soloway, Mark and Solsona, Eduardo and Sved, Paul and Babjuk, Marko and Brausi, Maurizio A. and Cheng, Christopher and Comperat, Eva and Dinney, Colin and Otto, Wolfgang and Shah, Jay and Thuerof, Joachim and Witjes, J. Alfred}},
  issn         = {{1873-7560}},
  keywords     = {{Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystoscopy; Diagnosis; Guidelines; Intravesical chemotherapy; Prognosis; Transurethral; resection (TUR)}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{36--44}},
  publisher    = {{Elsevier}},
  series       = {{European Urology}},
  title        = {{ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder}},
  url          = {{http://dx.doi.org/10.1016/j.eururo.2012.08.061}},
  doi          = {{10.1016/j.eururo.2012.08.061}},
  volume       = {{63}},
  year         = {{2013}},
}